In this article

A Nvidia logo is seen on the company's building at an industry park in Tianjin, China, Feb. 7, 2019.

CureVac — Shares of the German biopharmaceutical company continued to fall after it released primary efficacy results Wednesday for its Covid-19 vaccine candidate, which demonstrated an interim efficacy of just 47%. The stock closed down 39% Thursday.

Novavax — After CureVac reported disappointing results from a study of its Covid-19 vaccine, shares of Novavax added 2%. Novavax on Monday said its Covid vaccine is 90% effective.

In this article